GATM発現のためのスタチン依存のQTLは,スタチン誘発性筋痛症と関連しています
Lara M Mangravite1, Barbara E Engelhardt, Marisa W Medina
1Sage Bionetworks, 1100 Fairview Avenue North, Seattle, Washington 98109, USA. lara.mangravite@sagebase.org
Nature
|September 3, 2013
まとめ
スタチンはコレステロールを低下させますが,骨髄病を引き起こす可能性があります. GATM遺伝子を含む遺伝的リンクが発見され,スタチン誘発の筋肉損傷を潜在的に説明し,新しい治療目標を提供しました.
科学分野:
- ファルマコゲノミクスとは
- 分子生物学は分子生物学である.
- 心血管疾患に関する研究
背景:
- スタチンは,低密度リポプロテイン (LDL) と心血管疾患 (CVD) のリスクを減らすために広く処方されています.
- 利点はありますが,スタチンは,骨髄病や2型糖尿病などのリスクを伴います.
- スタチンの反応に影響を与える遺伝的要因は十分に理解されておらず,個別化された治療を制限しています.
研究 の 目的:
- スタチン治療のダウンストリームターゲットを特定する.
- スタチンの反応と毒性を調節する遺伝的変異を調査する.
- スタチンの使用と筋痛症を結びつけるメカニズムを探求する.
主な方法:
- in vitro スタチン暴露に対する反応として遺伝子発現の変化をスクリーニングする.
- スタチン試験参加者のリンフォブラストイド細胞系における遺伝子発現との遺伝的関連性を分析.
- 細胞モデルを使用して,スタチン誘発性筋毒性における特定された遺伝子の役割を調査する.
主要な成果:
- シムバスタチンと相互作用する6つの発現定量特征局部 (eQTLs) が特定されました.
- グリシンアミディノトランスフェラゼ (GATM) 遺伝子のシス-eQTLであるrs9806699は,スタチン誘発性筋毒性の減少と関連していた.
- GATMのノックダウンは,ステロールの枯渇に対する細胞応答を低下させ,コレステロール代謝と筋痛症の役割を示唆した.
結論:
- GATM遺伝子はスタチン治療のダウンストリーム標的であり,スタチン誘発性筋痛症の潜在的な仲介者です.
- GATMの遺伝的変異は,スタチン誘発の筋肉毒性に対する感受性に影響を与える可能性があります.
- GATMはコレステロールの調節とスタチンの副作用の間の機能的なリンクを表しています.
関連する概念動画
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Satellite Stem Cells and Muscular Dystrophy
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
